Kerala Ayurveda has informed that KAL reports 44% revenue growth in Q1 26 vs. PY (38% growth excluding Ayurvedagram Bali). Adjusted EBITDA* positive at Rs.6.4 Crs (+Rs.5.4 Crs. vs. PY) with continued investment in talent hiring, marketing and building infrastructure over the first quarter of 2026. KAL continues on its path to Double the growth rate in 2026 to 50% topline growth with investments in chosen drivers of growth - the Digital and Health service businesses powered by world class talent, marketing, technology and international expansion. Press release regarding the same enclosed.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1239.00 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 938.00 |
| Lupin | 2321.40 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: